The long road: improving outcome in elderly "unfit" AML?

Bob Lowenberg; Gerwin Huls

doi:10.1182/blood.2020005651

The long road: improving outcome in elderly "unfit" AML?

Bob Lowenberg^*, Gerwin Huls

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

2 Citations (Scopus)

43 Downloads (Pure)

Abstract

In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.

Original language	English
Pages (from-to)	2114-2115
Number of pages	2
Journal	Blood
Volume	135
Issue number	24
DOIs	https://doi.org/10.1182/blood.2020005651
Publication status	Published - 11-Jun-2020

Keywords

LOW-DOSE CYTARABINE
PLACEBO

Access to Document

10.1182/blood.2020005651

The long road improving outcome in elderly “unfit” AMLFinal publisher's version, 542 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{ca90d8f312254538bb9c11aaf4b037f6,

title = "The long road: improving outcome in elderly {"}unfit{"} AML?",

abstract = "In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.",

keywords = "LOW-DOSE CYTARABINE, PLACEBO",

author = "Bob Lowenberg and Gerwin Huls",

year = "2020",

month = jun,

day = "11",

doi = "10.1182/blood.2020005651",

language = "English",

volume = "135",

pages = "2114--2115",

journal = "Blood",

issn = "0006-4971",

publisher = "AMER SOC HEMATOLOGY",

number = "24",

}

TY - JOUR

T1 - The long road

T2 - improving outcome in elderly "unfit" AML?

AU - Lowenberg, Bob

AU - Huls, Gerwin

PY - 2020/6/11

Y1 - 2020/6/11

N2 - In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.

AB - In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.

KW - LOW-DOSE CYTARABINE

KW - PLACEBO

U2 - 10.1182/blood.2020005651

DO - 10.1182/blood.2020005651

M3 - Comment/Letter to the editor

SN - 0006-4971

VL - 135

SP - 2114

EP - 2115

JO - Blood

JF - Blood

IS - 24

ER -

The long road: improving outcome in elderly "unfit" AML?

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this